Over the past 20 to 30 years, the trend of improved pediatric AML treatment outcomes in major international clinical trials was significant1,10–12.Patients with RUNX1-RUNX1T1 benefited from being participants in several consecutive clinical trials, which consisted of intensive therapies based on either higher dose anthracycline or high-dose cytarabine10,28–30.Thomas et al. showed that patients with inv(16) also demonstrated the same trend in St. Here, RUNX1 is linked to acute myeloid leukemia.